GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aion Therapeutic Inc (XCNQ:AION) » Definitions » Profitability Rank

Aion Therapeutic (XCNQ:AION) Profitability Rank : 0 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aion Therapeutic Profitability Rank?

Aion Therapeutic has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Aion Therapeutic's Operating Margin % for the quarter that ended in Jan. 2024 was -107.66%. As of today, Aion Therapeutic's Piotroski F-Score is 6.


Competitive Comparison of Aion Therapeutic's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aion Therapeutic's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Profitability Rank falls into.



Aion Therapeutic Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Aion Therapeutic has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Aion Therapeutic's Operating Margin % for the quarter that ended in Jan. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=-0.239 / 0.222
=-107.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Aion Therapeutic has an F-score of 6 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Aion Therapeutic Profitability Rank Related Terms

Thank you for viewing the detailed overview of Aion Therapeutic's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Aion Therapeutic (XCNQ:AION) Business Description

Traded in Other Exchanges
Address
700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery.
Executives
Ismail Abdul Fattah Director or Senior Officer of 10% Security Holder

Aion Therapeutic (XCNQ:AION) Headlines

No Headlines